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Dear Colleague,
It is my pleasure to welcome you to the latest issue of the JHN Journal.
Spine surgery is continuously evolving with improvements in techniques,
and advancements in technology. As always, the Spine Surgeons at
Jefferson Health are at the forefront of this change.
Whether it’s the adoption of image guidance and robotics, implementation
of new minimally invasive techniques, advancements in neuromodulation,
or collaboration in novel therapies for spinal cord injury, Jefferson
Joshua E. Heller, MD, MBA

continues to lead the way.
This very special issue of the JHN journal will highlight some of the
important work that the Neurological Spine Surgeons at Thomas Jefferson
University Hospital, and Jefferson Abington Hospital are doing to improve
patient outcomes through advancements in technology.
I am very proud of the work that we do, and I am certain that the articles
contained within this issue will prove to be enlightening.

Sincerely,

Joshua E. Heller, MD, MBA
Associate Professor of Neurological
and Orthopaedic Surgery

Published by Jefferson Digital Commons, 2019

3

JHN Journal, Vol. 14 [2019], Iss. 1, Art. 6

Robert H. Rosenwasser, MD, MBA,
FACS, FAHA
Jewell L. Osterholm, MD, Professor and
Chair, Department of Neurological Surgery
Professor of Radiology, Neurovascular
Surgery, Interventional Neuroradiology
President/CEO, Vickie and Jack Farber
Institute for Neuroscience

James S. Harrop MD, FACS
Chief, Division of Spine and
Periphera Nerve Surgery
Neurosurgery Director of Delaware
Valley SCI Center
Neurosurgery Director for Adult
Reconstructive Spine

Medical Director, Jefferson Neuroscience
Network Senior Vice President, Jefferson
Enterprise Neuroscience

Jack Jallo, MD, PhD

Ashwini Sharan, MD

Professor of Neurological Surgery

Professor of Neurological Surgery
& Neurology

Professor & Vice Chair for
Academic Services

Program Director; Residency in
Neurological Surgery
Division Chief, Epilepsy and
Neuromodulatory Neurosurgery

Joshua E. Heller, MD, MBA

Srinivas Prasad, MD, MS

Associate Professor of Neurological &
Orthopedic Surgery

Associate Professor of
Neurological Surgery

Douglas W. Laske, MD
Chief, Division of Neurosurgery
Abington Health Physicians

Steven J. Barrer, MD
Director, Vickie and Jack Farber
Institute for Neuroscience at
Abington Medical
Director, Concussion Program

Jonas J. Gopez, MD

Michael S. Yoon, MD

Neurosurgical Associates of Abington
Health Physicians

Neurosurgical Associates of
Abington Health Physicians

https://jdc.jefferson.edu/jhnj/vol14/iss1/6
DOI: https://doi.org/10.29046/JHNJ.014.1

4

et al.: Full Issue: Volume 14, Issue 1 - Summer 2019

Table of Contents
Sacroiliac Joint Fusion — Impact of a New Image-Guidance Protocol on Safety
and Complications
Christian Hoelscher, MD; Daniel Franco, MD; Joshua Heller, MD, MBA ................................................ 2

Spinal Cord Injury: Current and Novel Treatment Strategies
Anthony Stefanelli, MD; Umma Fatema; Alexandra Emes; James Harrop, MD, FACS ........................9

Multiple Contiguous-Level Cervical Disc Arthroplasties: Unique Considerations
Alejandro J. Lopez, DO; Jonas Gopez, MD................................................................................................... 12

Minimal Access Expandable Mesh Device for Transforaminal Lumbar Interbody
Fusion: A Case Series
Ryan Moncman, DO; Michael Yoon, MD........................................................................................................ 16

Spinal Cord Stimulation in the 21st Century — Reviewing Innovation in
Neuromodulation
Victor Sabourin, MD; Justin Turpin, BA; Jeffrey Head, BA; Chengyuan Wu, MD;
Ashwini Sharan, MD; Christian Hoelscher, MD............................................................................................. 20

Recent Noteworthy Publications...........................................................................................................25

Published by Jefferson Digital Commons, 2019

5

JHN Journal, Vol. 14 [2019], Iss. 1, Art. 6

Sacroiliac Joint Fusion – Impact of a New ImageGuidance Protocol on Safety and Complications
Christian Hoelscher, MD; Daniel Franco, MD; Joshua Heller, MD, MBA

Technique – Fluoroscopy

Department of Neurological Surgery, Thomas Jefferson University, Philadelphia,
Pennsylvania, 19107

After administration of general endotracheal anesthesia and placement of
neuromonitoring leads, the patient is
positioned prone on a Jackson table
with careful attention to adequately
padding pressure points and ensuring
the abdomen hangs free. Fluoroscopy is
used to mark the skin on the ipsilateral
side the location of the sacral ala as well
as the posterior aspect of the sacral
canal. This serves as a marking point for
the incision and helps with orientation
of the implants (Figures 1-2). The skin is
then prepped and draped in standard
fashion. The incision is created with a
#10 blade and the subcutaneous tissue is
dissected with monopolar electrocautery.
A hemostat is used to open the fascia. A
Steinmann pin is placed at the level of the
ilium with lateral fluoroscopic guidance
at a location below the sacral ala. Pelvic
inlet and outlet views are obtained to
demonstrate adequate positioning of
the pin relative to the ilium, SI joint, and
neural foramina (Figure 3). The first pin
is then tamped through the ilium, across
the SI joint, and into the sacrum. The soft
tissue dilator is then placed over the pin,
followed by a soft tissue protector. A
drill is then advanced over the pin and
advanced across the SI joint. The broach
is then advanced across the SI joint
with fluoroscopic guidance on lateral,
pelvic inlet, and pelvic outlet views.
The broach is then removed. The first
implant is then advanced over the pin
and tamped into position using fluoroscopic guidance (Figure 4). A parallel pin
guide is then used to assist with placement of the next Steinmann pin inferior
to the first implant, and the procedure
is repeated for a second implant. The
parallel pin guide is then used to place
a Steinmann pin in the ideal location of
the third implant relative to the first two.
The authors preference is to place the
third implant it in a position anterior and
inferior to the first. The same procedure
is repeated for placement of the final

INTRODUCTION
Low back pain is a common affliction impacting patients worldwide. The burden of
low back pain on modern society in terms of direct costs associated with diagnosis and
treatment, as well as indirect costs such as time missed from work for both patients
and caregivers, is estimated to be as high as $100 billion annually in the United States
alone.1,2 Up to 2-3% of physician visits are thought to be related to chronic low back
pain.1,3 While the traditional focus of healthcare providers has been on lumbosacral
pathology, sacroiliac joint dysfunction is an underappreciated and underdiagnosed
cause of low back pain. Previous studies3-8 have suggested that 15-30% of chronic low
back pain is due to pathology located in the sacroiliac joint. Historically, recognition
of this pathology was difficult, limited by lack of standardized diagnostic criteria and
disease-specific outcome measures. Traditional treatment focused on conservative
therapy, such as physical therapy with focus on core and pelvic stability, orthoses,
pain and anti-inflammatory medication, weight loss, intra- or peri-articular injections, and radiofrequency ablation.4,5,9-12 Early surgical intervention came in the form
of morbid open approaches often utilizing iliac crest autografting. More recently,
minimally invasive techniques for sacroiliac fusion have been developed that allow
for significant sparing of muscle dissection, shorter operating room times and blood
loss, reduced length of stay, and fewer complications.13-17 Such techniques are often
performed with fluoroscopic guidance. However, three-dimensional sacral anatomy
can be challenging to conceptualize on fluoroscopic imaging and several centers are
now beginning to perform the procedure utilizing image-guidance with intraoperative
CT data. This is particularly helpful in patients with transitional lumbosacral anatomy
or those undergoing revision procedures. Complications such as pseudarthrosis and
neural injuries, while rare, are often associated with need for revision surgery and
poorer outcome.18,19 The transition to CT-based image-guidance aims to reduce such
complications. The purpose of this study is to review our series of minimally invasive
sacroiliac fusion with a focus on safety and complications, and to review differences
in these parameters between patients undergoing fluoroscopic technique versus
CT-based image-guidance.

METHODS
We performed a PubMed literature search utilizing the following terms: sacroiliac
joint fusion, SI joint fusion, minimally invasive, complications, image guidance. Only
English language articles were reviewed. All studies documenting large case series and
prospective trials regarding minimally invasive sacroiliac joint fusion were included.
The data extraction was performed by two reviewers (CH, DF), and reviewed by the
senior author (JH). The selected studies were analyzed, and relevant results were
reviewed. In addition, a retrospective review of minimally invasive sacroiliac joint
fusion procedures performed at our institution was performed spanning 2013-present.
Patient demographics, type of imaging used (traditional fluoroscopy versus CT and
Stealth image guidance) follow-up, and complications were recorded. Complications
of particular interest were neurologic complications, pseudarthrosis, and need for revision surgery, among others. Comparisons were made between patients undergoing
fluoroscopy and CT/Stealth guidance.
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A

Figure 1. Anatomic Landmarks
Relevant anatomic landmarks as seen on
a lateral fluoroscopic view
implant. Neuromonitoring signals are
checked after placement of each implant.
Final fluoroscopic images are obtained
confirming trajectory and final position across the SI joint into the sacrum
without breach of the neuroforamina.
The wound is then copiously irrigated
with antibiotic solution. The soft tissue
is anesthetized with Marcaine solution.
The deep dermal layer is closed with 2-0
vicryl suture in an inverted fashion and
the skin is closed with a 4-0 monocryl
subcuticular suture, followed by skin glue
and a sterile dressing.

Technique – CT/Stealth Image
Guidance
After administration of general endotracheal anesthesia and placement of
neuromonitoring leads, the patient is
positioned prone on a Jackson table
with careful attention to adequately
padding pressure points and ensuring
the abdomen hangs free. The low back
and lateral pelvic area on the side to be
fused are prepped and draped according
to standard protocol. A small incision is
made over the contralateral posterior
superior iliac spine (PSIS) with a #10
blade, and the fascia opened sharply with
monopolar electrocautery. The pin for
the Stealth reference frame is advanced
into the PSIS. The O-arm is then draped
and brought into the surgical field. After
confirmation of appropriate anteroposterior (AP) and lateral views centered
over the SI joint to be fused, an intraoperative CT is obtained and transmitted
to the Stealth work station. The O-arm is
then removed from the field. The passive
planar probe is used to mark the location
of the sacral ala on the skin, as well as

Published by Jefferson Digital Commons, 2019
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Figure 2. Incision Planning
Incision planning with pins placed along the sacral alae (A) and posterior sacral wall (B). The
incision is then created about 3 cm in length along the posterior sacral wall, approximately 1 cm
below the sacral alae (C).

A

B

C

Figure 3. Pin Placement
Pin placement about 1 cm below the sacral ala (A). Pelvic outlet views are obtained to advance
the pin parallel to the S1 endplate without breaching the sacral foramina (B). Pelvic inlet views
are obtained to ensure that the pin placement is appropriate in the anterior-posterior plane (C).
the location of the posterior aspect of
the sacral canal on the ipsilateral side.
This serves as the incision and reference
for graft placement. The skin is then
incised with a #10 blade, with dissection
carried down through the subcutaneous
tissue with monopolar electrocautery.
The fascia is opened with a hemostat.
The navigated universal drill guide is then
placed to the level of the ilium (Figure 5).
The first implant is planned and transferred
to the work station (Figure 6). The drill
guide is then used to place a guidewire
through the ilium to the planned depth. A
soft tissue dilator is then placed over the
wire, followed by a soft tissue protector.
The navigated drill is then used to drill
over the guidewire across the ilium, the
SI joint, and into the sacrum. The drill is
removed, and a navigated broach is then
advanced and tamped down the same
trajectory. Neuromonitoring is then
checked and confirmed to be unchanged

from baseline. The soft tissue protector
is then removed. A parallel pin guide
with a navigated universal drill guide is
then used to mark the location for the
starting point of the second implant,
inferior to the first graft. The process is
repeated for the second and third grafts.
Neuromonitoring is checked after placement of each graft. Once all grafts have
been placed, a second intra-operative
CT is obtained to confirm appropriate
positioning. The wound is then copiously
irrigated with antibiotic solution. The
soft tissue is anesthetized with Marcaine
solution. The deep dermal layer is closed
with 2-0 vicryl suture in an inverted
fashion and the skin is closed with a 4-0
monocryl subcuticular suture, followed
by skin glue and a sterile dressing. A
single monocryl suture is placed in the
contralateral PSIS pin site. Figure 7 shows
an example of post-operative imaging
demonstrating hardware position.
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baseline demographic and co-morbidities between the fluoroscopy and CT
groups, while Table 4 shows complications between the two groups. Baseline
demographics were notable for a trend
towards a higher proportion of females
and a higher proportion of revision
surgery in the CT cohort. Complications
were overall fairly rare and did not reach
statistical significance between groups.
There were 5 total complications in the
fluoroscopy group compared to two in
the CT cohort. There were 4 combined
cases of neurologic deficit and pseudarthrosis, all of which occurred in the
fluoroscopy group. Revision procedures
were required in 5 procedures utilizing
fluoroscopic guidance, compared to one
in the CT group.

A

B

DISCUSSION
Sacroiliac joint dysfunction is an increasingly-recognized source of low back pain.
This patient population has historically been
very difficult to treat, with an extremely high
burden of cost on both a direct and indirect
basis, often with frustrating outcomes and
high rates of persistent disability.3-5 The
traditional focus of back pain has been
on diagnosis and managing lumbosacral
pathology as well as neuropathic pain.
Sacroiliac evaluation is only more recently
gaining traction. Given that the SI joint is
the largest articular surface in the human
body, with fairly complex biomechanics
central to force transmission across the
complicated lumbosacral-pelvic anatomy,
it is not surprising that this may be another
source of pain.

C

Figure 4. Implant Placement
On pelvic outlet views, the drill is advanced over the pin (A), followed by broach placement
(B) followed by seating the final implant (C).

RESULTS
A total of 70 procedures were performed
on 67 patients. Baseline characteristics
and demographics are shown in Table 1.
The average age was 50.4, with a male:
female ratio of 49:21. BMI averaged 30.2.
Co-morbidities of interest included 9
patients with diabetes, 13 with lumbosacral
scoliosis, 5 with confirmed osteoporosis, 29
with a history of smoking, 5 active smokers,
and 37 with prior lumbar surgery. Followup averaged 7.6 months. A total of 5 cases
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were revision procedures. Forty-six procedures were performed utilizing fluoroscopy,
while 24 utilized CT with Stealth navigation.
Complications for the entire cohort are
demonstrated in Table 2. There was a total
of 7 complications noted: 2 neurologic
complications (both S1 radiculopathies),
two cases of pseudarthrosis, 2 hematomas, and one washout that revealed
only “thickened subfascial tissue”. Overall
7 patients underwent revision surgery.
Table 3 shows comparisons in terms of

Previous estimates of up to 30% of
chronic back pain being referable to the
SI joint have been published by numerous
authors.3-7 Recognition of this pathology
has been limited in the past by a lack of
clear diagnostic criteria. With increasing
focus on this clinical entity, there is starting
to be more consensus on appropriate
means of diagnosing SI joint dysfunction. Patient history will often reveal
pain in the gluteal region, located in the
region of the PSIS. This may or may not
be associated with a radiating component
down the lower extremity and/or into
the hip and groin. Pain is often worse in
the sitting position. Physical examination
is typically notable for positive findings
on the Fortin’s Finger test, as well as

8
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Figure 5. CT/Stealth Setup
A navigation pin is advanced into the contralateral PSIS and an intraoperative CT scan is
obtained (A). The navigated drill guide can then be advanced to the level of the ilium after
an appropriate incision has been made, and implant planning can proceed (B).

Figure 6. Implant Planning
Implant planning using the Stealth workstation).

reproduction of pain in at least three of
five provocative SI joint testing maneuvers
including pelvic distraction, thigh thrust,
direct compression, flexion/abduction/
external rotation (FABER), and Gaenslen’s
maneuver. Intrarticular SI joint injections
with local anesthetic are used to confirm
the diagnosis. Diagnostic injections relieve

Published by Jefferson Digital Commons, 2019

patient pain by at least 50-60% prior to
considering surgical fusion of the joint.
Therapeutic injections with steroid can be
used to try to provide longer lasting relief.
Evidence in favor of minimally invasive
SI joint fusion has largely been limited to
retrospective studies or smaller prospective cohort studies.8-11,14-17 Recently two

Sacroiliac Joint Fusion

large prospective, randomized controlled
trials (RCT) have been published lending
further support to the benefit of SI joint
fusion in carefully selected patients. Polly
et al20,21 performed an industry-sponsored trial of minimally invasive SI fusion
compared to best medical management.
A total of 148 patients were randomized
(102 to SI fusion, 46 non-surgical). The
primary endpoint was pain as measured
by VAS, with secondary endpoints
including disability on ODI, health-related
quality of life on the EuroQol-5D (EQ5D)
and Short Form 36 (SF 36). At 24-month
follow-up, VAS improved from 82.3 to
26.7 in the surgical group, compared
to 82.2 to 70.3 in the non-surgical
group. Similar disparity was noted on
ODI, EQ5D, and SF-36. At the 6-month
time point crossover was allowed, and
39/44 patients in the non-surgical group
elected for surgery and enjoyed similar
benefit as those originally randomized
to surgery. Overall complication rates
were not significantly different between
groups. Dengler et al8 performed a
prospective randomized trial, again
industry sponsored, that randomized
103 patients to minimally invasive fusion
(n=52) or conservative therapy (n=51).
The primary endpoint was back pain on
the VAS scale, with secondary endpoints
including leg pain VAS, ODI, EQ-5D,
and SI joint function via straight leg
raise. At 12-month follow-up there was
significant benefit of surgery compared
to conservative management across all
of these measures. Again, crossover was
allowed at 6 months. Crossover rates
were high, and benefits were similar to
those originally randomized to surgery.
The authors documented 6 procedurerelated complications, of which two
required revision surgery.
The focus of this study was complication avoidance and safety. This has
been explored by previous authors,
but to our knowledge no data is available comparing fluoroscopic versus
CT -based techniques. Schoell et al 18
performed the largest evaluation of
safety for SI fusion, reporting complication rates in a minimally-invasive SI
joint fusion patient population. They
used CPT and ICD-9 codes to identify primary (non-revision) minimally
invasive SI fusion procedures in a large
nationwide insurance database. They
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A

B

Figure 7. Post-Operative Imaging
Postoperative AP and lateral films showing final implant placement

Table 1. Baseline Characteristics
Age

50.4

M:F

49:21:00

BMI

30.2

Diabetes

9

Scoliosis

13

Osteoporosis

5

Prior Smoker

29

Current Smoker

5

Revision

5

Prior Lumbar Surgery

37

Fluoro:Nav

46:24:00

Baseline demographics and co-morbidities for patients undergoing SI fusion.

Table 2. Complications for the Entire Cohort
Value

Sacral radiculopathy

2

Pseudoarthrosis

2

Other

3

Revision

7

This table demonstrates complication profiles for the entire cohort.
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identified a total of 469 patients and
noted an overall complication rate of
13.2% within 90 days, and 16.4% within
6 months. Notable complications at 90
days and 6 months respectively included
new lumbar pathology (3.6% and 5.3%),
infection (3.6% and 4.1%) “nervous
system” complications (4.3% and 6.2%),
and chronic pain (2.6% and 4.1%). These
rates of complications are somewhat
higher than compared to previously
published RCT and prospective cohort
studies, particularly in regard to infection
with has often been quoted around 1%
for minimally invasive SI fusion.8-11,1417,20,21
Review of our complication data
confirms the safety of the procedure,
with an overall complication rate of 10%
at mean follow-up of 7.6 months. Of note,
we had no cases of infection. There were
3 washouts performed (2 hematoma, one
which noted only “thickened subfascial
tissue”). Our transition to O-arm image
guidance appears to have had a positive impact on the complication profile,
although the overall low patient numbers
and complication rate has prevented
this difference from reaching statistical
significance as yet. Of particular interest
to this study was our rate of neurologic
deficit and symptomatic pseudarthrosis;
two cases of each occurred, both in the
fluoroscopic group. While rare, when such
complications occur, they almost invariably
result in revision surgery with possible longterm implications for patient outcome.
Proper implant placement is critical to
avoiding such complications and should be
improved with more precise image guidance. While fluoroscopy is a useful adjunct
in this regard, the need for sophisticated
understanding of sacro-pelvic anatomy on
pelvic inlet, pelvic outlet, lateral, and other
views can present a steep learning curve.
Revision surgery and transitional anatomy
can make the procedure more difficult,
even in very experienced hands. Threedimensional image guidance such as CT
with Stealth navigation is helpful in this
regard, and the lack of implant misplacement in our cohort of 24 navigated cases,
even with a significantly higher proportion
of revision cases in this group, is a testament to that. An additional consideration
in terms of complications and safety worth
mentioning is successful fusion across the
joint. Our study is limited in that we do not
have routine post-operative References
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7. Schmidt GL, Bhandutia AK, Altman DT.
Management of Sacroiliac Joint Pain. J Am
Acad Orthop Surg. 2018 Sep 1;26(17):610-616.

Table 3. Baseline Characteristics Between Groups
Fluoro (n=46)

CT (n=24)

P-Value

Age

50.6

49.9

*

M:F

17:29

4:20

0.078

BMI

30.5

29.5

*

Diabetes

5

4

*

Scoliosis

9

4

*

Osteoporosis

4

1

*

Prior Smoker

18

11

*

Current Smoker

4

1

*

Revision

1

4

<0.05

Prior Lumbar Surgery

24

13

*

This table demonstrates baseline characteristics and comorbidities between the two groups. *
denotes a p-value > 0.1.
Table 4. Baseline Characteristics Between Groups
Fluoro (n=46)

CT (n=24)

P-Value

Sacral radiculopathy

2

0

*

Pseudoarthrosis

2

0

*

Other

1

2

*

Revision

5

2

*

This table demonstrates complication profiles for both groups. * denotes a p-value > 0.1.

CT scans to evaluate bony bridging across
the SI joint. Previous studies have quoted
fusion rates at 1-2 years postoperative in
the range of 80-97%.15,17,19 Two of our
patients had documented symptomatic
pseudarthrosis requiring revision, both in
the fluoroscopy group. However, overall
statements regarding solid fusion across
the SI joint are difficult to generate with
our data given the lack of protocolized
follow-up CT imaging.
This study has limitations. Most notable
is the retrospective nature of the analysis,
and relatively low patient numbers.
Furthermore, the duration of follow-up
in this cohort is short, and longer-term
follow-up would be helpful. Fusion across
the SI joint was difficult to assess, and a
standardized protocol for post-operative
CT imaging to formally evaluate this
would be helpful to get a better understanding of pseudarthrosis rates.

Published by Jefferson Digital Commons, 2019
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INTRODUCTION
The care and treatment of spinal cord injury (SCI) patients has significantly evolved
over the last several decades. There has been great interest and promising research
conducted over this period resulting in advancement of our understanding of the
pathophysiology of SCI on both a biochemical and biomolecular level. Concurrently, there has also been rapid clinical advancements in treating spinal fractures
with improvement in the understanding of the biomechanics of injuries, as well as
improvements in spinal fixation techniques and devices. In addition, there have been
great strides made in the collaborative care and treatment efforts of SCI patients
particularly in the fields of radiology, rehabilitation, trauma, and intensive care.
The developments in SCI treatment have led to a decrease in the overall incidence
of traumatic injuries, particularly in the younger populations. This is mainly a result
of preventative measures and education by the various foundations who focus on
the treatment of SCI patients such as CSRS, ASIA, AAOS, CNS, and AANS. In addition,
there has been a greater emphasis in society on limiting catastrophic injuries such as
through the use of: airbag immobilization in motor vehicles, helmets, and the overall
reduction of high-risk activities.
To provide some background information on the pathophysiology of a traumatic SCI,
it is believed that SCI is multifaceted, with the initial force or compression of the cord
resulting in the primary injury. This is then followed by an inflammatory or biochemical
response that results in further injury to the cord over the subsequent days to weeks.
This is referred to as the secondary injury, and it is this stage of injury that has been the
target of intense research. Currently, there exists multiple novel strategies in dealing with
this secondary injury component including surgical techniques, medical management,
pharmacology, and cell-based therapies which will be discussed below.

SURGICAL TECHNIQUES
Over the last century, it is been established that early decompression of the spinal
cord results in improved neurologic outcomes. However, not until the publication of
the STASCIS study (PLoSOne. 2013 Aug 23;8(8):e72659) has clinical data significantly
demonstrated that early decompression does, indeed, improve neurological outcome.
This study, in which Jefferson Health was the highest enrolled center, showed that
surgical decompression and stabilization in less than 24 hours gave the patient the
greatest chance of improving by up to two neurologic grades in the ASIA scale.
Another area of exciting research has been the use of a biocompatible scaffold polymers for acute spinal cord injury, which is also an option for patients at Jefferson
Health. This scaffold is surgically inserted into the spinal cord at the site of injury and
will break down over several weeks. It is postulated that this polymer modulates the
healing environment in acute injury and provides the structural support in both acute
and chronic injury necessary to promote a local environment supportive of cell survival
and growth within the spinal cord. The INSPIRE trial, a study from InVivo therapeutics
(http://www.invivotherapeutics.com) examined the potential benefit of this NeuroSpinal Scaffold (TM) for safety and neurologic recovery in patients with complete
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Figure 1.
Sagittal T2-weighted MRI demonstrating
post spinal cord injury with increased
signal and edema within the cervical
cord (arrow) along with superimposed
cervical stenosis
thoracic (T2-T12) spinal cord injury. This
study is currently being analyzed and
there appears to be a neurologic benefit
with use of this polymer scaffold. Larger
and more comprehensive studies will
likely take place following final analysis
of the data from this trial.

MEDICAL MANAGEMENT
The medical intensive care treatment of
the patients after their traumatic SCI is also
extremely important in overall recovery
and prognosis. It has been determined
throughout the last several decades that
increased blood flow to the spinal cord
by maintaining patients with an elevated
mean arterial pressure significantly
improves neurologic recovery. This is
akin to elevating the blood pressure in an
acute stroke patient so as to perfuse the
brain penumbra that has not yet reached
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Figure 3.
(Left) Sagittal T2-weighted MRI and (Right) CT scan demonstrating a thoracic flexiondistraction injury (fracture dislocation) causing severe spinal cord compression
Figure 2.
Intraoperative lateral radiograph
demonstrating post-surgical instrumented
posterior cervical fusion hardware
terminal ischemia. In addition, there is
interest in the use of hypothermia to
decrease the metabolic bands of the spinal
cord during the acute phase of injury to
help aid in recovery. Jefferson is currently
involved in this study through a grant from
the Department of Defense.

by blocking the rho activation system. In
the initial phase 1 study, which compared
the medication to case controls, not
only was the medication safe, but it also
showed to be efficacy. Unfortunately,
when the medication was compared
to placebo there was no significant
improvement, so the trial was ultimately
halted. However, the study did result in
greater interest in the investigation of
drugs to treat and modulate injuries to
the spinal cord.

PHARMACOLOGY
The largest international SCI pharmacological multicentered prospective
randomized controlled study is presently
being run through the AO Foundation.
Jefferson is currently the largest clinical
enrolling site in North America. This study
is investigating the drug, Riluzole, which
is approved for patients with ALS, and its
effect on reducing excitatory apoptosis
(cell-initiated death) after an injury to the
spinal cord. This is a continuation of a
phase 1 study, also done at Jefferson,
which showed safety of the medication.
Unfortunately, not all promising initial
studies are confirmed during their phase
3 trials. Recently, Jefferson was involved
with the Vertex SCI trial which examined
a medication to prevent cell apoptosis
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CELL-BASED THERAPIES
There is a good deal of excitement about
the possibility of cell mediated interventions being used to improve neurologic
outcomes after SCI. We are very fortunate at Jefferson to have been asked to
participate in many studies investigating
this topic and strategy. The first stem cell
spinal cord injury trials were performed
by Geron Corporation, although, they
were eventually halted and sold to
a secondary company that became
known as Asterias (https://asteriasbiotherapeutics.com). Asterias has been a
proponent of intraparenchymal spinal
cord injection of stem cells. Unlike some
other cell-based strategies, these do not
target the neurons directly but rather the

oligodendrocytes, which function to
provide support and myelin production
in the central nervous system.
In another trial, named the StemCell Inc
trial, HuCNS stem cells were implanted
through direct spinal cord parenchymal
injections within one year of the injury.
Despite showing promising improvements
in neurologic recovery, the study was
unfortunately halted due to financial issues.
Currently, there is an active trial investigating the use of Schwann cell transplants
being performed at the University of
Miami. This study uses Schwann cells
harvested from the patient and transfers
them directly into spinal cord injury site.
The results of the phase 1 portion of this
trial were published in 2017 and showed
the safety of this treatment, noting that
there were no adverse events or serious
adverse events related to the cell therapy.
It is important to realize, however, that
that with any new treatment, there can
be significant complications. Particularly
related to cell-based therapies, such as
implantation of stem cells, there is the
possibility for inducing aberrant growth of
non-spinal cord tissue which has potential
to harm the surrounding neural structures.
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ABSTRACT
Arthroplasty is an established treatment for single and multiple level cervical disc
disease. Multiple contiguous arthroplasties introduce unique changes in spinal kinematics that warrant study independent of single-level surgery. The literature regarding
the biomechanics, indications, outcomes and complications specific to multiple level
arthroplasties was reviewed. Appropriate application of this technology has been
shown to be a safe and potentially advantageous alternative to arthrodesis.

INTRODUCTION
Cervical disc arthroplasty (CDA) is an alternative to anterior cervical discectomy and
fusion (ACDF) for the treatment of cervical disc disease. Developed with the intention
of preserving or restoring motion of a degenerated disc, CDA has been proposed to
reduce rates of adjacent segment degeneration and disease.1-4
A single-level ACDF reduces the cervical range of motion approximately 7 degrees,
while CDA preserves or may even increase motion at that segment.5-10 The benefit
of replicating physiologic motion to prevent adjacent segment disease has been the
subject of debate, with several current meta-analyses advocating the use of CDA over
ACDF for single level disease for this reason.11-13 Evidence includes a randomized control
trial reporting a significant decrease in the rate of subsequent surgery at 7 years follow
up for single level CDA compared to ACDF.14
The generalizability of these data to multilevel disease is unclear. Inclusion criteria for
many randomized controlled trials excluded multilevel treatments or, if multilevel CDA
was included, those data were often not analyzed independently of single-level results.
The purpose of this review is to examine the unique considerations and literature of
multilevel CDA.

BIOMECHANICS
Adjacent segment disease (ASD), defined by Hilibrand as new and symptomatic degenerative changes after fusion,15 has been attributed to compensatory biomechanical
stresses at levels above and below a fusion,16 which approximately 25% of patients who
undergo ACDF will experience within 10 years from surgery.17 Most biomechanical
studies on multilevel CDA were designed to investigate this phenomenon.
The degree of additional stress at adjacent levels is commonly quantified by measurements of intradiscal pressure and mobility.16,18 In multilevel ACDF, adjacent discal
pressures have been shown to increase by 3-6.7 fold, while CDA either maintains or
even decreases adjacent level pressures.19-22
In a cadaveric load-control study, Phillips found that a single CDA at C5/6 increased
flexion-extension of that motion segment by 4 degrees but did not significantly change
rotation or lateral bending. The adjacent segments’ motions were unchanged. Upon
implanting a second CDA at C6/7, lateral bending of the superior adjacent level (C4/5)
increased. A single CDA at C6/7 did not reproduce the increase in flexion-extension

12

https://jdc.jefferson.edu/jhnj/vol14/iss1/6
DOI: https://doi.org/10.29046/JHNJ.014.1

JHN JOURNAL

or adjacent level mobility. This suggests
that multilevel arthroplasty introduces
unique spinal kinematics and that the
effects may be level-dependent. In vivo,
multilevel arthroplasty has demonstrated
no significant difference from pre-operative motion at the operated levels. 23, 24
Authors have proposed that biomechanical
stresses are additive with consecutive levels
of arthrodesis due to increased constraint
and suggest that arthroplasty may help
defray the mechanical disadvantages of
a multilevel fusion;16 however, a recent
meta-analysis reported that the highest
prevalence of ASD was in single level
ACDF, significantly more than in multilevel
fusion.25 This contradicts finite element
analyses wherein longer segment anterior fusions have been shown to increase
adjacent level intradiscal stresses.26 While
the authors of the meta-analysis suggest
that multilevel procedures might have
already addressed the most at-risk levels,
the etiologies of ASD and how the biomechanics of arthroplasty affect them have
not been fully reconciled with clinical data.

INDICATIONS/PATIENT
SELECTION
Multiple devices have FDA approval for
single and multilevel cervical disc arthroplasty. Randomized controlled trials
on multilevel arthroplasty selected for
patients with degenerative disc disease
causing radiculopathy or myelopathy
and excluded patients with pathology
outside of C3-7. 23, 24, 27 Expanded indications have been reported, including
acute traumatic disc herniations28 and
use in upper thoracic levels. 29
Contraindications include less than three
millimeters of available disc space to avoid
excessive loading of the posterior elements
by overdistracting anteriorly.30 Kyphotic
deformity of greater than 15 degrees may
indicate concomitant posterior element
pathology that could be exacerbated by
increasing motion at that segment. Other
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contraindications include active infection,
malignancy, and metabolic or inflammatory spine diseases. Osteoporosis may
increase the risk for implant migration.31

B

CASE EXAMPLE
A 45-year-old Caucasian male presented
with eight months of neck pain with radiation down his right arm to his right thumb,
index and middle finger. There was no
inciting event or trauma. He was neurologically intact other than a right Spurling’s
sign. There was no clinical evidence of
myelopathy.
On review of his cervical MRI, he had
advanced spondylosis with right greater
than left neural foraminal narrowing at
C5-6. Spondylosis with bilateral foraminal
narrowing was also noted at C6-7. (Figure 1)

Figure 1.
Post-operative lateral (A) and anterior/posterior (B) radiographs showing stable cervical
alignment and adequate positioning of consecutive cervical arthroplasties.

A

B

He was treated with several weeks of physical therapy, cervical traction, and three
epidural steroid injections without lasting
improvement in his symptoms. Given his
failure of conservative treatment, surgical
decompression was recommended. The
options of arthrodesis and arthroplasty
were offered to the patient, who elected
to undergo C5/6 and C6/7 arthroplasties.
Post-operatively, he recovered very well
with complete resolution of his preoperative neck and arm symptoms. Radiographs
confirmed adequate cervical alignment
and device placement. (Figure 2) By 8
weeks post-op, he had returned to work
without restrictions as an electrician.

OUTCOMES

C

Figure 2.
Sagittal T2 MRI showing multi-level spondylotic changes without disc space collapse
or kyphotic deformity (A). Axial MRI through the C5/6 (B) and C6/7 (C) disc spaces
demonstrating broad based disc bulging that results in right foraminal stenosis at C5/6 and
bilateral foraminal stenosis at C6/7.
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Initial trials excluded multiple level
arthroplasties or combined them with
single level treatments in their analyses.
In 2007, Pimenta reported that 2 or 3 level
CDA experienced significantly greater
improvements in patient outcomes —
Neck Disability Index (NDI) and Visual
Analogue Score (VAS) — than single level
arthroplasty at 3 years from surgery. 32
Subsequent studies addressed multilevel
disease independently.
One class-one randomized, controlled trial
has been published comparing patients
who underwent single and multiplelevel CDA. Clinical outcome scores
were not significantly different between
the two arms: both groups had similar
NDI, VAS, Short Form 12 (SF-12 MCS/
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PCS), and satisfaction scores. The rate of
complications, subsequent surgeries, and
heterotopic ossification were also not
significantly different. 27
In a systematic review, Joaquim identified
two class-one randomized, controlled
trials that compared contiguous multilevel arthroplasties against arthrodesis.33
In a 330 patient study, Davis found positive patient-reported outcomes with CDA:
a significant decrease in NDI and SF-12
PCS that was maintained for 4 years of
follow up and improved patient satisfaction scores. Neck pain and arm pain VAS
scores were not significantly different,
though neck pain scores were transiently
lower with arthroplasty. ACDF had a
higher rate of subsequent surgery on the
index level, 4.0 vs 15.2%, predominantly
for symptomatic pseudoarthrosis.23
Radcliff conducted a second randomized,
controlled trial in 325 patients. Similarly,
NDI and SF-12 PCS were significantly
lower with arthroplasty at all postoperative time points through 5 years
of follow up. There was no difference in
VAS scores for arm or neck pain. Again, a
lower probability of subsequent surgery
on index or adjacent levels was identified
with arthroplasty. Range of motion was
not significantly changed from pre-operative values by CDA. Rates of adjacent
segment degeneration were assessed by
the Kellgren-Lawrence scale: CDA had
significantly less degeneration (50.7%)
than arthrodesis (90.5%). These two
studies suggest that ASD is not prevented
by CDA, but patients with multilevel
arthroplasty may develop radiographic
changes and become symptomatic at
a slower rate than those with multilevel
ACDF for at least five years.24

COMPLICATIONS
Anterior cervical arthroplasty and
arthrodesis share a similar complication
profile due to their common surgical
approach. Xu conducted a systematic
review of arthroplasty trials and reported
dysphagia/dysphonia at rates of 1.3 to
27.2%, vascular injury including hematoma at 1.1 to 2.4%, dural injury at 0.0 to
7.1%, and wound infection at 1.2 to 22.5%.
Dysphagia is a well-described approachrelated complication to anterior cervical
surgery. In a cadaver model, placing
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three-level anterior cervical plate fixation was found to cause five-fold higher
intraesophageal pressures than what is
required to place equivalent level arthroplasties due to increased retraction.34 A
prospective, randomized trial showed
a decrease in dysphagia on the BazazYoo scale with zero-profile arthroplasty
compared to arthrodesis with plate fixation.35 The etiology of the dysphagia may
be attributable to the increased dissection and retraction required to introduce
the plate or from the presence of a
foreign body within the retropharyngeal
space. Consecutive interbody fixation
devices without an anterior plate may
obviate this benefit of arthroplasty.
Heterotopic ossification (HO) is a
common complication of prosthetic
joints, wherein new bony growth may
inhibit movement of the prosthesis
or cause compression of the neural
elements. The McAfee classification
divides HO of CDA into grades I/II,
which comprise radiographic findings
of bony growth and grades III/IV, which
have clinical manifestations of limited
movement. 36 The pooled prevalence of
HO in single and multilevel CDA across
multiple studies has been reported as
58.2% at 2 years, with a 16.7% rate of
grade III or above.37 Wu reported higher
rates of HO in two-level arthroplasty
(75.0%) compared to single level (40.5%),
with 14.3% of arthroplasties losing their
mobility after multilevel surgery. 38 In
prospective trials of two-level arthroplasty, rates of clinically significant HO
were 16.6% 23 and 29.7%. 24 Arthroplasties
at C3/4 may also have higher levels of HO
due to decreased physiologic motion at
that level compared to the other subaxial
segments.39
Implant migration is a rare complication
of CDA that may produce iatrogenic
injury. The largest report of symptomatic migrations comprised 5 patients
who underwent single or multiple-level
CDA in a single institution, with an overall
rate of 0.4% of all cervical arthroplasties
performed.40 In four cases, the device
was explanted and revised with ACDF
and in one patient, the implant was
simply removed. Zhai reported a case
of migration in a two-level arthroplasty
that presented with dysphagia and was
revised with a corpectomy of the middle
vertebra and multilevel fusion.41 Of the

large prospective trials on multiple level
arthroplasties, only one case of migration was reported in a study of 255
patients with 4 years of follow-up. 23
Sagittal fracture while preparing superior
and inferior keels in a single vertebra is
a unique complication of subsequent
level arthroplasty. The few case reports
available suggest that this is a rare
phenomenon and may be managed with
a rigid cervical collar, though prolonged
post-operative pain may occur.42

CONCLUSION
Multilevel CDA has demonstrated unique
biomechanics and complication profiles
compared to arthrodesis and single-level
arthroplasty. Multilevel arthroplasty
offers advantages in patient-reported
outcome measures to arthrodesis in
appropriately selected patients.
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ABSTRACT
Bone-sparing techniques for transforaminal lumbar interbody fusion (TLIF) are
promoted to help maintain spinal stability and to minimize operative time. We present
a series of seven patients who underwent TLIF with use of an interbody expandable
mesh device and with supplemental instrumentation. This device is deployed and filled
with bone through a small cannula. All patients experienced pain relief and suffered no
complications. Our results support the data from other centers which have performed
similar procedures with this device.
Keywords: transforaminal lumbar interbody fusion, OptiMesh, deployable mesh,
minimal access

INTRODUCTION
Lumbar interbody devices can be difficult to insert from a posterior approach due to
their sizes and shapes, especially when the disc space is significantly collapsed (Figure
5). In addition, stabilizing posterior elements are removed in order to create a clear
corridor to the disc space. A less invasive approach to the disc space involves the placement of a collapsed, expandable mesh pouch (OptiMesh by Spineology, St. Paul, MN).
The pouch is gradually filled with increasing amounts of allograft bone chips through
the small portal. (Figure 1) The mesh itself is made out of polyethylene terephthalate, a
non-absorbable and pliable material commonly used in vascular grafts. We describe a
series of patients who underwent this procedure with supplemental instrumentation.
Spineology OptiMesh graft containment system has been approved for the treatment
of stable vertebral body defects. The device has also been used in the disc space
for interbody fusion. 2,5,6,7,8,9 The OptiMesh portal, despite its low profile, allows for
an extensive discectomy and with preparation of the endplates, especially when the

Table 1.
Patient Info

16

TLIF level, type

Follow up

Outcome Compared to Pre-op

1.

66 yo F

L2-3 open

29 months

90% overall pain relief

2.

49 yo M

L3-4 open

24 months

95% overall pain relief

3.

73 yo F

L1-2 open

18 months

90-95% overall pain relief

4.

66 yo M

L4-5 open

17 months

80-85% overall pain relief

5.

42 yo M

L5-S1 open

5 months

50% overall pain relief

6.

57 yo F

L4-5 percutaneous

3 months

95% overall pain relief

7.

46 yo M

L4-5 percutaneous

4 weeks

Preoperative lower
extremity pain resolved.
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Figure 1.
Spineology OptiMesh
cannulas are introduced bilaterally. The
bone chips are packed into the mesh
until good filling of the disc space is
noted on fluoroscopic imaging.

CASE PRESENTATIONS
From August 2016 through January 2019,
seven patients underwent lumbar transforaminal interbody fusions by the senior
author using the mesh containment
device with supplemental instrumentation, either interspinous clamps (Patients
2, 3 and 5) or bilateral pedicle screws/rods
(Patients 1,4,6 and 7). Five patients had
the interbody device placed with some
minimal bony removal. Two patients
had the mesh inserted via a purely
percutaneous, bone-sparing approach
via Kambin’s triangle (Figures 2 and 3).4
We utilized neuromonitoring for the
percutaneous approaches.
Patient 1 was a 66-year-old female who
presented with five years of low back pain
and one year of right lower extremity
pain. An MRI revealed retrolisthesis of L2
on L3, which had progressed slightly over
seven years. There were stable findings
of anterolisthesis at L4-5 and at L5-S1.
Patient 2 was a 49-year-old male with
many years of back pain with one year of
paresthesias and numbness in the bilateral lower extremities. An MRI showed
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regained her strength and sensation
but her preoperative, chronic low back
pain and left lower extremity pain had
worsened after the procedure. An MRI
revealed very severe degenerative disc
disease at L1-2 with Modic changes. Also
noted were postoperative changes at L4
to S1.
Patient 4 was a 66-year-old male with
chronic lower back pain which had
worsened over six months. He also
complained of bilateral lower extremity
weakness when going up or down stairs.
Physical exam revealed no objective
weakness. An MRI revealed a grade I
spondylolisthesis at L4-5 with Modic
changes and moderate central stenosis.
Patient 5 was a 42-year-old male with
a history of end-stage renal disease
and had presented to the hospital
with severe, intractable low back pain
radiating into the left lower extremity.
An MRI showed evidence of a discitis
at L5-S1 and cultures from a needle
biopsy by interventional radiology grew
Staphylococcus epidermidis. Despite
initial antibiotic treatment and narcotic
medications, he remained in severe
intractable pain. He did have a history of
chronic low back pain.
Patient 6 was a 57-year-old female who
had undergone a right hemilaminectomy
and bilateral sublaminar decompression
at L4-5. She continued to have bilateral
lower extremity pain two months after
surgery, and dynamic radiographs had
demonstrated abnormal motion at L4-5.

Figure 2 and 3.
Intraoperative fluoroscopic images on patient number 7 show the percutaneous
instrumentation being placed into the bilateral disc spaces via Kambin’s triangle.
The disc is removed and the endplates prepared. The OptiMesh is then introduced
and filled gradually with granular bone graft.

a moderate left-sided L3-4 disc/osteophyte complex with severe degenerative
collapse and Modic changes. Similar
findings, to a lesser degree, were seen
at L5-S1.

Published by Jefferson Digital Commons, 2019

Patient 3 was a 73-year-old female who
had undergone an emergent laminectomy at an outside institution for
sudden-onset bilateral lower extremity
weakness three months earlier. She

Patient 7 was a 46-year-old male who
had undergone an L5-S1 instrumented
interbody fusion nine years ago. He
had developed progressive low back
and bilateral lower extremity pain, left
greater than right. An MRI showed some
mild degenerative disc disease at L4-5
but dynamic radiographs revealed instability at this level with a solid fusion at
L5-S1. This particular patient required
revision of his existing hardware in order
to couple it to the new pedicle screws
which were inserted into L4. However,
the interbody mesh was delivered via an
entirely percutaneous approach.
All patients experienced pain relief
compared to preoperatively with no
complications (nerve root injuries, durotomies, infections, or hardware failures). All

JHN JOURNAL

21

17

JHN Journal, Vol. 14 [2019], Iss. 1, Art. 6

Figure 4.
Postoperative CT on patient number 7 show the interbody graft in good position at L4-5.
The previous L5-S1 interbody fusion is also seen.

patients, except for number 5, had failed
conservative management including
physical therapy and/or epidural steroid
injections. Follow up ranged from 2 weeks
to 28 months.

Figure 5.
Preoperative CT on patient number
4. Arrow points to narrow corridor for
insertion of a TLIF cage.

DISCUSSION AND
CONCLUSIONS
In order to place a typical interbody
cage via a TLIF, the unilateral facet joint
is generally removed in its entirety. Standard TLIF cages measure from 7 mm
to 16 mm in height with 10 to 11 mm
width. The Spineology OptiMesh cannula
measures 7 mm in diameter; all the bone
chips that fill the mesh are delivered
through this size portal. The mesh
allows for much less bony removal and
also the option of a purely percutaneous
approach requiring no bony removal via
a trajectory through Kambin’s triangle.
The rigidity and contour of most interbody devices often causes undesired
trauma to the vertebral endplates during
insertion. Weakening of the endplates
could contribute to settling of bone
over the interbody construct. The mesh
appears to conform well to a patient’s
unique endplate shape and integrity
(Figure 7). Moreover, the density of
the inserted bone chips should more
closely match that of a patient’s own
bone than polyetheretherketone (PEEK)
or metal, theoretically reducing the risk
of subsidence.
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Figure 6.
Postoperative CT on patient number 4.
The placement of the interbody graft is in
the anterior disc space and the lordosis
is maintained. Such placement of a
graft would be difficult to achieve from
a posterior approach with a traditional
interbody device due to the narrow entry
point through the dorsal disc space.
Lordotic cages have a leading edge which
are larger than the tail end.

Various expandable interbody cages are
available, but most devices expand only
in the sagittal plane, not in the axial and
coronal ones. The OptiMesh expands in
all planes and, as mentioned, contours to

Figure 7.
Postoperative CT scan on patient number
6 shows the mottled appearance of the
endplates with the OptiMesh device
within the disc space. The unhealthy
endplates make placement of a very rigid
device undesirable.

the shape of the actual disc space. The
PEEK or metal used in most interbody
devices also occupy significant space,
whereas the mesh allows for more
surface area contact for bone to remodel
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and potentially increase the likelihood of
a robust bony fusion.
Based on our limited experience, the
mesh device is a safe, effective option for
TLIF. Its main advantages appear to be
decreased anatomical disruption during
delivery and deployment, the ability to
expand in all planes with conformity to
the endplates, and greater surface area
contact of bone for remodeling and
fusion. A study involving a larger number
of patients and further long-term follow
up is warranted.

REFERENCES
1. Chiu JC, Maziad AM: Post-traumatic
Vertebral Compression Fracture Treated
with Minimally Invasive Biologic Vertebral
Augmentation for Reconstruction. Surg
Technol Int. 1:268-77, 2011

Published by Jefferson Digital Commons, 2019

2. Hsuan-Kan Chang, John Paul G Kolcun,
Peng-Yuan Chang, Michael Y Wang;
Enhanced Recovery After Surgery™ Awake
Minimally-Invasive Transforaminal Lumbar
Interbody Fusion: 2-Dimensional Operative
Video, Operative Neurosurgery, opy187,
https://doi.org/10.1093/ons/opy187
3. Inamasu J, Guiot BH, Uribe JS: Flexiondistraction injury of the L1 vertebra treated
with short-segment posterior fixation and
Optimesh. J Clin Neurosci. 15(2):214-8, 2008
4. Kambin P, Sampson S. Posterolateral percutaneous suction-excision of herniated lumbar
intervertebral discs. Report of interim results.
Clin Orthop Relat Res. 1986;207:37–43
5. Krag, M (2009): Prospective Evaluation of a
Conformable Interbody Bone Graft Container.
Presented at The International Society for the
Study of the Lumbar Spine. Miami, FL.

Expandable Mesh Device

6. Nucci, R (Nov 2010): Outpatient Instrumented
Anterior/Posterior Lumbar Fusion. Presented
at Society for Minimally Invasive Spine
Surgery. Miami, FL.
7. Perez-Cruet M, Lauryssen C, Krag M H, et al
(2006): Novel Expandable Interbody Fusion
Device: Results of a Multicenter IDE Feasibility
& Safety Study. Presented at the College of
Neurological Surgeons. Chicago, IL.
8. Zahrawi F (April 2010), Minimally Invasive
Fusion Using Deployable Mesh Filled with
Allograft and BMP. Presented at The Annual
Global Symposium on Motion Preservation
Technology. New Orleans, LA.
9. Zheng, Xiujun et al. Biomechanical evaluation
of an expandable meshed bag augmented
with pedicle or facet screws for percutaneous
lumbar interbody fusion. The Spine Journal.
10(11): 987 - 993, 2010

JHN JOURNAL

23

19

JHN Journal, Vol. 14 [2019], Iss. 1, Art. 6

Spinal Cord Stimulation in the 21st
Century — Reviewing Innovation in
Neuromodulation
Victor Sabourin, MD1; Justin Turpin, BA2; Jeffrey Head, BA2; Chengyuan Wu, MD1;
Ashwini Sharan, MD1; Christian Hoelscher, MD1
1
2

Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA, 19107
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 19107

INTRODUCTION
Low back pain (LBP) is a pervasive problem impacting health systems across the world.
In the United States, chronic LBP impacts up to 40% of Americans and results in excessive financial strain on the healthcare budget, estimated at up to $100 billion annually.1
Furthermore, treatment results are often disappointing, with the traditional pathway of
conservative measures, narcotic pain medication, and surgical decompression and/or
fusion leading to both patient and provider frustration, complications, and diminished
patient productivity and quality of life. This has naturally led to questions from policymakers regarding the utility of healthcare dollars spent on back pain. In this milieu, a
variety of neuromodulation techniques have found a niche in the management of this
patient population, with indications commonly quoted including failed back surgery
syndrome (FBSS), chronic neuropathic pain, and complex regional pain syndrome
(CRPS), among others.1,2 From its inception on the basis of Melzak and Wall’s gate
theory³, to its first human trial in the 1960s,⁴ and to the modern era, spinal cord
stimulation has undergone a series of innovations that have expanded indications and
improved patient outcomes. The goal of this study is to summarize the most important
clinical trials involving both traditional SCS and newer stimulation paradigms to provide
an overview of the current state of affairs of this rapidly-growing field.

METHODS
We performed a PubMed literature search utilizing the following terms: SCS, spinal
cord stimulation, neuromodulation, high frequency stimulation, paresthesia free,
HF10, failed back surgery syndrome, and chronic pain. Only English language articles
were reviewed. All prospective, randomized controlled trials pertaining to the use of
neuromodulation in the treatment of chronic back and limb pain were included. The
data extraction was performed by three reviewers (JT, JH, CH), and reviewed by the
senior author (CW). The selected studies were analyzed, and relevant results were
summarized as follows.

RESULTS
Traditional, Low Frequency, Tonic SCS
Several landmark trials paved the way for the widespread use of spinal cord stimulation in the treatment of chronic back and limb pain. These early studies utilized low
frequency stimulation generally in the 40-100 Hz range delivered in a tonic manner,
producing paresthesias that overlap the areas where the patient experiences pain.
North et al5 randomized 51 FBSS patients with chronic lower limb pain with or without
back pain to initial treatment with a low frequency stimulator or re-operation. The
primary endpoint was “success”, defined as > 50% reported pain relief and patient
satisfaction with treatment at 2-years post-operatively or at last follow-up. Secondary
end points included treatment crossover, success at last follow-up, and improvement in medication use, daily activities, and neurologic status. At mean three-year
follow-up, “success” was achieved in a significantly higher proportion of patients
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randomized to SCS (47%) compared to
those randomized to reoperation. 5,6
These findings remained statistically
significant even after worst-case analysis
which assumed patients unavailable for
long-term follow-up in the SCS group
were all treatment failures. Further, a
significantly higher proportion of patients
in the reoperation arm crossed over to
SCS (54%) compared to only 21% of SCS
patients who elected to undergo reoperation. While patient reported functional
capacity didn’t reach a significant difference, SCS patients did require significantly
fewer opiate equivalents for pain control.
Kumar et al 7,8 followed this up with the
PROCESS study which randomized 100
FBSS patients with limb>back pain to
SCS with medical management (n=52)
or medical management alone (n=48).
The primary end point of the study was
defined as > 50% relief of leg pain, with
secondary end points including quality
of life, functional capacity as measured
by the Oswestry Disability Index (ODI),
patient satisfaction, and changes in pain
medication usage. At 6-month followup, the primary endpoint was achieved in
48% of SCS patients compared to 9% in
the medical management alone group.
The SCS group also reported significantly
greater quality of life, improvement in ODI,
treatment satisfaction, and reduced back
pain compared to medical management
alone. SCS patients were also more likely
to reduce drug intake based on morphine
equivalents as well as decrease use of nondrug therapies. Similar improvements were
maintained at 12 and 24 month follow-up
analyses.7,8

Paresthesia-Free SCS
As clinical experience with traditional,
paresthesia-based systems grew, interest
began to develop in creating new stimulation protocols that would generate
pain relief without the need for paresthesia overlap as a significant number
of patients found these sensations to be
uncomfortable, particularly when there
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is significant postural variation which
can make certain daily activities, such
as driving, difficult or painful. Furthermore, traditional spinal cord stimulation,
while relatively successful at treating
appendicular neuropathic symptoms,
struggled with relief of more nociceptive
axial pain where adequate paresthesia
overlap is difficult to achieve. Given how
common low back pain is in the general
population, a more efficient means for
targeting this symptom complex was
needed. Buyten et al 9 prospectively
enrolled 82 patients with back pain with
or without associated leg pain in a trial
of high frequency, low amplitude, paresthesia free stimulation using the Nevro
device. The outcomes of interest were
VAS scores, ODI, sleep disturbances per
night, and patient satisfaction. The trial
to conversion rate was 88%. VAS back
and leg scores improved at 6 months, 8.4
to 2.7 for back and 5.4 to 1.4 for leg pain.
ODI improved by 17 points and patients
reported 2.4 fewer episodes of sleep
disturbance per night. Similar results
were obtained with HF10 therapy in
another prospective observational study
in patients with a primary complaint low
back pain, with back pain and leg pain
reduced by 61% and 58%, respectively,
based on VAS10. While promising, these
and other observational studies did not
provide a control group to compare
against. To that end, De Andres et al11
compared high frequency (10 kHz)
stimulation to conventional stimulation,
randomizing 55 patients with FBSS with
neuropathic back or leg pain. The results
suggested no significant difference at
one year, with both stimulation profiles
showing significant benefit compared
to baseline values.11 On the other hand,
North et al,12 in their pilot study randomizing patients with FBSS who had a
previously implanted, paresthesia-based
system with inadequate pain relief, noted
that pain relief via NRS and disability
via ODI were significantly improved
with 1 kHz stimulation. 12 Perruchoud
and colleagues 13 similarly randomized patients with chronic neuropathic
back and leg pain, previously stable on
a conventional SCS system, to periods
of sham and 5 kHz, subthreshold tonic
stimulation. The periods of sham and
5 kHz stimulation were separated by
a “washout” period during which the
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patients reverted to their traditional,
paresthesia-based pattern. The primary
outcome was the Patient’s Global
Impression of Change (PGIC), with
secondary outcomes including VAS
and the Euroqol questionnaire EQ-5D.
At the end of the study, the authors
noted no difference between sham and
high-frequency stimulation, with what
appeared to be a “period effect” in that
patients tended to respond more favorably to sham or 5 kHz stimulation based
purely on which was initiated first and
responded less favorably to whichever
pattern was tested second. However,
the comparison to baseline values is
confusing and again the use of previously
stabilized tSCS patients is a variable that
must be considered. The most robust
data in this field came from Kapural and
colleagues who explored the ability of
low amplitude, high frequency spinal
cord stimulation at 10 kHz to provide
durable relief of both axial and appendicular pain in the SENZA trial.14,15 In this
prospective, multicenter, randomized trial,
the investigators randomized 198 patients
with medically refractory back and leg
pain to either high frequency stimulation (HF10) or traditional low frequency,
paresthesia-dependent treatment (tSCS).
The primary endpoint was >50% reduction on the visual analog scale (VAS), with
secondary outcomes including opioid
use, functional disability as measured by
ODI, and percentage change from baseline back and leg symptoms. A total of
171 patients had positive trials and were
ultimately implanted (HF10, n=90; tSCS,
n = 81). At the initial 3-month evaluation, 84.5% of HF10 patients achieved
the primary endpoint for back pain,
compared to only 43.8% of tSCS patients.
Similarly, for leg pain HF10 success on the
primary endpoint was 83.1% compared
to 55.5% for tSCS. These values remained
similar at 12-month follow-up evaluation, with remission rates (VAS <2.5) for
back and leg pain approaching 67% for
HF10, compared to 35-40% for tSCS.
At 24-month evaluation, the difference
in primary endpoint success was still
maintained in favor of HF10 for both
back and leg pain (76.5% and 72.9%
respectively for HF10, compared to ~50%
for tSCS). Secondary outcome analysis
also favored HF10, with greater overall
percentage reduction of back and leg
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pain compared to baseline, higher likelihood of achieving minimal disability on
ODI, and higher patient reported treatment satisfaction. Additionally, 11.3%
of patients in the tSCS group reported
uncomfortable paresthesias, with no
patients in the HF10 group reporting any
paresthesia-related issues.14,15
Despite accumulating clinical evidence
regarding the efficacy of high frequency
SCS, several questions remained. One such
issue is the impact of varying frequencies
and other stimulation parameters on treatment effect. One study16 prospectively
randomized a cohort of 24 patients into a
blinded crossover study, with each patient
experiencing 3 weeks at a time of sham
stimulation, and stimulation at 1200 Hz,
3030 Hz, and 5882 Hz. The devices were
programmed such that amplitude was
maintained slightly below threshold level,
unique to each patient and frequency.
The primary outcome was the reduction
of VAS back pain scores. Baseline VAS
was reported at 7.75, with improvement
to 4.83, 4.51, 4.57, and 3.22 for the trial
groups (sham, 1200 Hz, 3030 Hz, and
5882 Hz, respectively). All comparisons
to baseline were significant, but within
the treatment groups only 5882 Hz had a
significantly greater impact on outcome.
The authors argued that while designed
as a study on frequency, the impact of
pulse width on allowable amplitude
without generating paresthesia yielded
higher charger-per-second dosing with
higher frequency stimulation, which
may have played a role in the results.
The results also questioned to what
degree pain relief afforded by spinal cord
stimulation is a result of placebo, as at
the end of the study 12.5% of patients
preferred the sham stimulation protocol.
A similar study also explored the impact
of varying degrees of high-frequency
stimulation on treatment effect, noting
the unclear mechanism of HF10 and the
unclear impact of frequency on clinical
outcome. In this study, Thomson et al 17
randomized 21 patients with chronic
back>leg pain who had passed a trial of
10 kHz stimulation and were implanted
with permanent devices. Each patient
experienced four weeks of stimulation,
in random order, at 10 kHz, as well as 1-,
4-, and 7 kHz. At each frequency, pulse
width and amplitude were adjusted to
optimize therapy. The impact on the
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primary outcome, NRS for back, leg, and
overall pain, was similar between groups
with all frequency groups showing about
50% reduction in each category. There
were no between-group differences.
There was significantly less charge
delivered in the 1 kHz stimulation than in
the other three groups. Interestingly, the
calculated charge delivered per second
showed a non-linear relationship with
frequency, suggesting that frequency
modification in isolation may not deliver
appropriate symptom relief, highlighting
the importance of the interplay between
frequency, pulse width, and amplitude.
As interest in paresthesia-free stimulation
grows, other investigators are exploring
novel stimulation protocols. Burst stimulation, a technique based on short intervals
of high-frequency, low amplitude stimulation followed by periods of inactivity, is one
such protocol thought to work in at least
two mechanisms: 1) more closely mimic
neuronal firing in the central nervous
system with impacts on higher-order thalamo-cingulate pathways, and 2) provide
inhibition of Aδ and c fibers via subthreshold
antidromic Aβ activation with resultant
activation of inhibitory interneurons. De
Ridder et al18 performed an early trial with
this technology, randomizing 15 patients
undergoing a trial of spinal cord stimulation
to 7 days each of burst, tonic, and sham
stimulation. Primary endpoints included
VAS for back, limb, and general pain, with
secondary endpoints including the pain
vigilance and awareness scale (PVAQ), and
worst/best pain levels during a given trial
week. They noted that burst stimulation
did not induce more paresthesias than
sham stimulation. The primary outcome
measure showed significant improvements in back, limb, and general pain
comparing burst stimulation to placebo.
Because burst stimulation produced no
noticeable paresthesias, this marked the
first time in a randomized trial that spinal
cord stimulation could be proven better
than control/sham treatment, an important
landmark in SCS research. Not surprisingly,
tSCS showed significant improvement in
limb and general pain, but not back pain,
compared to placebo. Comparing burst
to tSCS, the mean change in back pain
favored burst (-3.8 on VAS compared to
-2.2), but this did not reach significance.
Limb pain between the two protocols
was the same (both -3.9 on VAS). General
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pain was significantly reduced with burst
therapy (-4.5 VAS) compared to tSCS
(-2.5). Regarding the PVAQ, tonic and
placebo stimulation showed no impact
on attention to pain or attention to
changes in pain, whereas burst stimulation
significantly improved these parameters,
suggesting an impact on affective and
attentional components of pain. Schu et al
19
compared high frequency stimulation to
a burst protocol, randomizing 20 patients
with FBSS and a previously implanted,
burst-capable system to separate, one
week periods of placebo stimulation, 500
Hz tonic stimulation, and burst stimulation
(5 pulses at 500 Hz, delivered 40 times
per second), with the primary outcome
of interest the impact on the numerical
rating scale (NRS) for pain intensity. Baseline values were obtained prior to entering
the protocol, with the device programmed
for standard, paresthesia-based stimulation. While burst stimulation was the only
pattern to significantly reduce the NRS
score, the magnitude of the treatment
effect was modest (5.6 at baseline, 4.7
for burst stimulation), and disability as
measured by ODI showed only a nonsignificant decrease. However, it is worth
reiterating that the “control” values in this
study were based on patients stabilized
on a paresthesia-based system, and thus
treatment effects can be expected to be
blunted, and the fact that at the end of
the trial 80% of the patients preferred the
burst protocol is also significant. More
recently, Deer et al20 published results of
the SUNBURST trial, which randomized
patients with refractory back and leg pain
to tSCS or burst stimulation. The trial was
conducted in two phases. First patients
were randomized to a 12-week period of
a given stimulation treatment, and then
switched to the other stimulation method
for the next 12 weeks. Thereafter, the
patients were allowed to choose their
preferred stimulation method and were
assessed every 6 months for two years.
The primary endpoint was change in VAS.
A total of 100 patients were randomized,
with 45 entering tSCS first followed
by burst, and 55 vice versa. At 12- and
24-week analyses, both non-inferiority
and superiority of burst stimulation as
compared to tSCS were established via
the primary endpoint of VAS reduction.
Secondary endpoint analyses revealed that
61.6% of patients were paresthesia-free

with burst compared to only 2.7% of
tSCS patients. While 78.1% of patients
were satisfied overall with both stimulation methods, 70.8% reported preferring
burst stimulation with lack of paresthesia
being the most common reason cited.
This preference was maintained at oneyear follow-up with 68.2% of patients
continuing to prefer burst therapy. Much
like high frequency stimulation, as the
clinical efficacy became clear, more questions emerged regarding mechanisms and
the impact of various stimulation parameters. One study21 randomized 15 patients
previously implanted with a burst-capable
device in the setting of FBSS to one of two
stimulation patterns: 1) 5 pulses delivered
at 500 Hz with a 1000 µsec pulse width, 40
times per second or 2) 5 pulses delivered at
1000 Hz, 1000 µsec pulse width, 40 times
per second. The amplitude, and thus the
total electrical dose delivered remained
the same. Clinical outcomes were not
significantly different.

DISCUSSION
Spinal cord stimulation was first put
into clinical practice in the 1960s for
an attempt at palliation in a patient with
terminal cancer pain.4 The momentum
behind its initial development was
the ubiquitous Gate Control Theory
put forth by Melzack and Wall. 3 While
generally accepted that this theory is
overly simplistic regarding the mechanism of action in the various spinal
cord stimulation techniques, it did
inspire generations of physicians and
scientists to develop new means of
tackling medically refractory chronic
pain syndromes. 22 Traditional, lowfrequency, suprathreshold tonic spinal
cord stimulation has been postulated
to work via several mechanisms. Most
commonly cited includes selective
activation of large, myelinated Aβ fibers
with subsequent inhibition of smaller,
pain-mediating Aδ and c fibers via
inhibitory interneurons. Other postulated contributors include dorsal horn
wide dynamic range neurons, thought to
develop a hypersensitivity in neuropathic
injury states with resultant increased
basal glutamate release and subsequent
glutamate:GABA imbalance. Supraspinal
mechanisms are also thought to be at
play although the exact brainstem-spinal
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circuitry activated by spinal cord stimulation remains largely theoretical. 22
Regardless of the inner workings of
the therapy, spinal cord stimulation has
proven to be an important development
in the management of an otherwise
frustrating patient population. Medical
management in chronic pain conditions
often fails and is associated with high
rates of narcotic medication use with
their associated complications. Futile
treatment regimens, although inexpensive in isolation, become expensive
when applied indefinitely, and costly
revision surgeries without clearly rectifiable structural or compressive pathology
are not only low yield, but very expensive
and potentially dangerous. Spinal cord
stimulation has provided an opportunity
to attain symptom relief, limit disability,
and improve patient productivity. And
although the upfront investment is
large, there is an increasing amount of
evidence suggesting that the long-term
cost-effectiveness profile is positive
and that spinal cord stimulation should
be considered earlier in the broader
treatment paradigm for chronic pain.1,2
With all of this said, spinal cord stimulation is certainly no panacea. One of
the most important limiting factors is
the requirement for a high-degree of
overlap between induced paresthesia
and the patient’s baseline pain. This
becomes a problem for patients that
can’t tolerate even mild paresthesia.
Furthermore, positional differences in
the intensity of elicited paresthesia have
been reported by some patients, and
occasionally even limit participation in
important day-to-day activities such as
driving. The requirement for paresthesia
overlap also makes the treatment of
axial symptoms particularly challenging,
as effective paresthesia coverage in this
region remains elusive even with today’s
technology. Given that chronic back pain
is one of the most common problems
in modern medical systems, achieving
efficient low back coverage is a priority
for next generation models.
With these challenges in mind, innovation in spinal cord stimulation has moved
towards paresthesia-free systems. Burst
patterns were developed as a means
of subthreshold stimulation that would
more closely resemble central nervous
system neuronal firing. Furthermore,
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simultaneous SCS/EEG studies have
suggested that burst stimulation impacts
cortical medial pain pathways, with De
Ridder et al 18 showing an effect on
connectivity involving dorsolateral
prefrontal, dorsal anterior cingulate,
and parahippocampal regions. In other
words, burst stimulation may impact
affective and attentional components
to pain in addition to pain transmission.
High-frequency, low-amplitude stimulation patterns have been developed
ranging up to 10,000 Hz. Again, the exact
mechanism of action of these systems
remains elusive, but several hypotheses
have been put forth, including production of a local sodium channel blockade
with inhibition of depolarization within
the dorsal columns, desynchronization of neuronal messaging from the
periphery, and inhibition of wide dynamic
range neuronal sensitization, among
others. 22 What is clearer is that the
clinical benefit has been demonstrated
in several randomized controlled trials,
most notably the SENZA trial14,15 where
both axial and limb pain response rates
approached 70% up to two years after
implantation. From a surgical perspective, the purely anatomic placement of
HF10 leads creates additional benefit
in terms of ease of placement for the
surgeon, without the need for uncomfortable wakeup testing for the patient
and likely shorter overall anesthesia time.
However, such systems are not without
their limits, as well. There is a certain
subset of patients that prefer paresthesias, ostensibly as a reassuring cue that
there is in fact a therapy being provided.
Furthermore, very high frequency systems
such as HF10 deliver much more charge
per second, which can lead to short
internal pulse generator (IPG) lifetime,
or in the case of rechargeable IPGs,
significant charging burden for the
patient. Additionally, the exact impact
of frequency, amplitude, and pulse
width, and thus total charge delivery, are
unclear and have not been systematically
accounted for in the available literature.
It is highly likely that simple frequency
modulation is not by itself responsible
for the clinical benefit of this technique,
and a clearer understanding of how
these parameters come together for
therapeutic effect will be critical if we are
to maximize the potential benefit.

Modern Spinal Stimulation

CONCLUSION
Chronic back pain remains a highly prevalent clinical problem in modern society.
This patient population has historically
been very challenging to treat. Spinal
cord stimulation has helped to bridge
the treatment gap in these patients, and
while progress so far has been encouraging, there remains much research to
be done to fully understand the mechanisms and potential therapeutic reach of
this modality.
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UPCOMING JEFFERSON
NEUROSURGERY CME PROGRAMS
A

s a part of the Vickie and Jack Farber Institute for Neuroscience at Jefferson, the Department of Neurological
Surgery is one of the busiest academic neurosurgical programs in the country, offering state-of-the-art treatment to
patients with neurological diseases affecting the brain and spine, such as brain tumors, spinal disease, vascular brain
diseases, epilepsy, pain, Parkinson’s disease and many other neurological disorders (Jefferson.edu/Neurosurgery).
As part of a larger educational initiative from the Jefferson Department of Neurological Surgery, the Sidney Kimmel
Medical College Office of Continuing Professional Development is offering the following continuing professional
educational opportunities for 2019:

• 8th Annual Jefferson Neurocritical Care Symposium
Friday-Saturday, February 22-23, 2019
Dorrance H. Hamilton Building, Center City Campus
of Thomas Jefferson University

• 18th Annual Cerebrovascular Update
Thursday-Friday, March 14-15, 2019
The Bellevue, Philadelphia, PA

• 5th Annual Philadelphia Spine Summit
Friday, May 10, 2019
Dorrance H. Hamilton Building, Center City Campus of
Thomas Jefferson University

• 9th Annual Brain Tumor Symposium
October 25, 2019
Philadelphia, PA

• 2nd Annual New Jersey
Neurovascular Symposium
November 2019

• 31st Annual Pan Philadelphia
Neurosurgery Conference
December 6, 2019
The Union League of Philadelphia
For additional information regarding these and other Jefferson CPD
programs, please visit our website at CME.Jefferson.edu or call the Office
of CPD at 877-JEFF-CPD (877-533-3273).
Sidney Kimmel Medical College at Thomas Jefferson University is
accredited by the ACCME to provide continuing medical education
for physicians.
Many of the activities above offer additional CE accreditations.
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Jefferson Health
Where Breakthroughs Happen

• One of the largest brain tumor programs in the nation and currently
researching a new immunotherapy for treating glioblastomas
• Internationally recognized experts in endovascular neurosurgery,
performing more than 400 aneurysms and brain AVM
procedures a year
• One of the first and only clinical, academic and research centers
dedicated to headache disorders
• Specialists treating more spine disorders and injuries than any
other hospital in the region
• One of the highest volume medical and surgery epilepsy centers
in the nation, with some of the country’s most experienced
specialists in neurostimulation implantation

Thomas Jefferson
University Hospital

The Vickie and Jack Farber Institute for Neuroscience –
Jefferson Health – where the brightest minds are preventing,
treating and finding cures for brain and spine disorders.
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